Lewis B. Silverman, MD

Lewis B. Silverman, MD

Pediatric Hematology/Oncology

Contact Information

Fax

617-632-5710

Appointments

888-733-4662 (New Pediatric Patients)
617-632-3270 (Established Pediatric Patients)

Biography

Lewis B. Silverman, MD

Dr. Silverman received his MD from Harvard Medical School in 1991 and training in pediatrics at Boston Children's Hospital in 1994. He subsequently completed a fellowship in pediatric hematology-oncology at Boston Children's Hospital and Dana-Farber Cancer Institute. In 1997, he became an attending physician in pediatric hematology-oncology at Dana-Farber/Boston Children's, and today, he is Vice Chair of Clinical Affairs, Department of Pediatric Oncology, at Dana-Farber Cancer Institute and Associate Chief, Pediatric Oncology, at Boston Children's Hospital. Dr. Silverman also leads the DFCI/ALL Consortium, which conducts multi-institutional clinical trials for children and adolescents with newly diagnosed acute lymphoblastic leukemia.

Researcher

Physician

Vice Chair for Clinical Affairs, Department of Pediatric Oncology
Associate Chief, Pediatric Oncology, Boston Children's Hospital
Institute Physician
Professor of Pediatrics, Harvard Medical School

Clinical Interests

Acute lymphoblastic leukemia (ALL)

Board Certification

  • Pediatric Hematology/Oncology, 1998

Fellowship

  • Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology

Residency

  • Boston Combined Residency Program, Boston Children's Hospital/Boston Medical Center, Pediatrics

Medical School

  • Harvard Medical School

Research

    Childhood Acute Lymphoblastic Leukemia

    Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Fifty years ago, childhood ALL was universally fatal, but today long-term event-free survival rates are nearly 80%. Despite this improved outcome, therapy remains nonspecific and toxic. The Dana-Farber Cancer Institute ALL Consortium has been conducting clinical trials in childhood ALL for over 30 years, with a focus on improving survival while minimizing toxicity. A major focus of our research has been to improve the tolerability of the drug asparaginase. Asparaginase is an important agent used to treat children with ALL, but up to one-third of patients experience significant side effects from it, and those who are unable to receive all of the intended asparaginase doses have a higher relapse rate. We are currently conducting a trial comparing intravenous PEG-asparaginase with intramuscular E. coli asparaginase to determine if the former is associated with less toxicity. We also have attempted to minimize the cardiac toxicity related to another drug, doxorubicin. In a randomized trial, patients received doxorubicin either with or without dexrazoxane, a potential cardioprotectant agent. Significantly fewer patients treated with dexrazoxane had elevations of troponin T (a serum marker of cardiac injury), and those who did had notably lower elevations, suggesting that dexrazoxane prevented doxorubicin-induced cardiac damage. We continue to monitor long-term cardiac function, and are investigating pharmacogenomic predictors of late cardiac toxicity. We also continue to study and test strategies to minimize other potential late effects in long-term survivors, including neurocognitive late effects and bony morbidity (such as osteonecrosis). Importantly, we have recently identified a new prognostic factor: minimal residual disease (MRD) levels. Molecular techniques can be used to measure levels of residual leukemia in patients who, by microscopic evaluation, are in complete remission. We found that patients with relatively high MRD levels at the end of one month of treatment had a much higher risk of relapse than those with lower MRD levels. In our current clinical trial, we are intensifying therapy for patients with high MRD levels in an attempt to improve their outcome. We continue to pursue the development of targeted therapies that are more leukemia-specific and less toxic. Areas of interest include Notch 1 inhibitors (for patients with T-cell ALL), mTOR pathway inhibitors (to reverse corticosteroid resistance) and flt-3 inhibitors (for patients with MLL gene rearrangements). Because of our unique adult-pediatric consortium, we will be able to test these and other novel targeted agents in patients regardless of age.

    Publications

      • Inequitable Poverty Exposures: A Subspecialty Opportunity to Address Disparities. Hosp Pediatr. 2024 Feb 01; 14(2):e104-e106. View in: Pubmed

      • Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia. 2024 Jan 05. View in: Pubmed

      • ETV6 fusions from insertions of exons 3-5 in pediatric hematologic malignancies. Haematologica. 2023 Dec 01; 108(12):3471-3476. View in: Pubmed

      • Disparities in parental distress in a multicenter clinical trial for pediatric acute lymphoblastic leukemia. J Natl Cancer Inst. 2023 10 09; 115(10):1179-1187. View in: Pubmed

      • Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials. Blood Adv. 2023 09 26; 7(18):5234-5245. View in: Pubmed

      • Impairment of health-related quality of life for children with acute lymphoblastic leukemia over the first year of therapy: A report from the DFCI ALL Consortium. Pediatr Blood Cancer. 2023 11; 70(11):e30560. View in: Pubmed

      • Outlier Expression of Isoforms by Targeted or Total RNA Sequencing Identifies Clinically Significant Genomic Variants in Hematolymphoid Tumors. J Mol Diagn. 2023 09; 25(9):665-681. View in: Pubmed

      • Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2023 Jul; 10(7):e510-e520. View in: Pubmed

      • Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia. Blood Adv. 2023 04 11; 7(7):1092-1102. View in: Pubmed

      • A systems approach points to a therapeutic role for retinoids in asparaginase-associated pancreatitis. Sci Transl Med. 2023 03 15; 15(687):eabn2110. View in: Pubmed

      • Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study. Blood. 2023 02 16; 141(7):704-712. View in: Pubmed

      • Feasibility of serial neurocognitive assessment using Cogstate during and after therapy for childhood leukemia. Support Care Cancer. 2023 Jan 10; 31(2):109. View in: Pubmed

      • "There's no playbook for when your kid has cancer": Desired elements of an electronic resource to support pediatric cancer communication. Pediatr Blood Cancer. 2023 03; 70(3):e30198. View in: Pubmed

      • Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/KMT2A Rearrangements in a Modern Therapy Era: A Retrospective International Study. J Clin Oncol. 2023 03 01; 41(7):1404-1422. View in: Pubmed

      • Oral Mercaptopurine Adherence in Pediatric Acute Lymphoblastic Leukemia: A Survey Study From the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium. J Pediatr Hematol Oncol Nurs. 2023 Jan-Feb; 40(1):17-23. View in: Pubmed

      • Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001). Haematologica. 2022 10 01; 107(10):2295-2303. View in: Pubmed

      • Feasibility of oncology clinical trial-embedded evaluation of social determinants of health. Pediatr Blood Cancer. 2022 11; 69(11):e29933. View in: Pubmed

      • Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR). Pediatr Blood Cancer. 2022 11; 69(11):e29901. View in: Pubmed

      • Reply to: Comment on: Ocular abnormalities at diagnosis and after the completion of treatment in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Pediatr Blood Cancer. 2023 Jan; 70(1):e29833. View in: Pubmed

      • JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. Leukemia. 2022 06; 36(6):1499-1507. View in: Pubmed

      • Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. Blood. 2022 03 24; 139(12):1785-1793. View in: Pubmed

      • Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana-Farber Cancer Institute ALL Consortium trial 05-001. Pediatr Blood Cancer. 2022 08; 69(8):e29581. View in: Pubmed

      • Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia. Br J Haematol. 2022 08; 198(3):421-430. View in: Pubmed

      • Clinical Characteristics and Short-Term Outcomes of Children With Asparaginase-Associated Pancreatitis. J Pediatr Gastroenterol Nutr. 2022 Mar 01; 74(3):402-407. View in: Pubmed

      • Integrative RNA-omics Discovers GNAS Alternative Splicing as a Phenotypic Driver of Splicing Factor-Mutant Neoplasms. Cancer Discov. 2022 03 01; 12(3):836-855. View in: Pubmed

      • Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001. Blood Adv. 2022 02 22; 6(4):1329-1341. View in: Pubmed

      • Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials. Blood Adv. 2022 01 11; 6(1):72-81. View in: Pubmed

      • Ocular abnormalities at diagnosis and after the completion of treatment in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Pediatr Blood Cancer. 2022 04; 69(4):e29542. View in: Pubmed

      • Hyperglycemia during induction therapy for acute lymphoblastic leukemia is temporally linked to pegaspargase administration. Pediatr Blood Cancer. 2022 07; 69(7):e29505. View in: Pubmed

      • Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol. Eur J Cancer. 2022 01; 160:72-79. View in: Pubmed

      • Impact of Risk-Stratified Therapy on Health Status in Survivors of Childhood Acute Lymphoblastic Leukemia: A Report from the Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev. 2022 01; 31(1):150-160. View in: Pubmed

      • Master Protocols and Adaptive Trial Designs to Develop Tumor-Agnostic Drugs for Children: Essential Tools in the Era of the Research to Accelerate Cures and Equity Act. JAMA Oncol. 2021 09 01; 7(9):1281-1282. View in: Pubmed

      • Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. J Clin Oncol. 2021 11 01; 39(31):3496-3505. View in: Pubmed

      • Impact of acute lymphoblastic leukemia induction therapy: findings from metabolomics on non-fasted plasma samples from a biorepository. Metabolomics. 2021 06 27; 17(7):64. View in: Pubmed

      • Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood. 2021 05 06; 137(18):2463-2480. View in: Pubmed

      • Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. Cancer Discov. 2021 06; 11(6):1424-1439. View in: Pubmed

      • Genetic ancestry and skeletal toxicities among childhood acute lymphoblastic leukemia patients in the DFCI 05-001 cohort. Blood Adv. 2021 01 26; 5(2):451-458. View in: Pubmed

      • Corrigendum. Pediatr Blood Cancer. 2021 Mar; 68(3):e28885. View in: Pubmed

      • Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 01; 68(1):e28719. View in: Pubmed

      • Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction. Pediatr Blood Cancer. 2021 01; 68(1):e28574. View in: Pubmed

      • Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion. ESMO Open. 2020 09; 5(5):e000977. View in: Pubmed

      • How we approach Philadelphia chromosome-positive acute lymphoblastic leukemia in children and young adults. Pediatr Blood Cancer. 2020 10; 67(10):e28543. View in: Pubmed

      • Reduced Morbidity and Mortality in Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2020 10 10; 38(29):3418-3429. View in: Pubmed

      • HLA alleles associated with asparaginase hypersensitivity in childhood ALL: a report from the DFCI Consortium. Pharmacogenomics. 2020 06; 21(8):541-547. View in: Pubmed

      • Protective Effects of Dietary Intake of Antioxidants and Treatment-Related Toxicity in Childhood Leukemia: A Report From the DALLT Cohort. J Clin Oncol. 2020 07 01; 38(19):2151-2159. View in: Pubmed

      • Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma. Blood Adv. 2020 04 14; 4(7):1265-1269. View in: Pubmed

      • Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 01; 18(1):81-112. View in: Pubmed

      • Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019 12 26; 134(26):2361-2368. View in: Pubmed

      • Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. PLoS One. 2019; 14(11):e0221288. View in: Pubmed

      • Genes identified through genome-wide association studies of osteonecrosis in childhood acute lymphoblastic leukemia patients. Pharmacogenomics. 2019 11; 20(17):1189-1197. View in: Pubmed

      • Impact of DARC, GSDMA and CXCL2 polymorphisms on induction toxicity in children with acute lymphoblastic leukemia: A complementary study. Leuk Res. 2019 11; 86:106228. View in: Pubmed

      • Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. J Clin Oncol. 2019 09 01; 37(25):2246-2256. View in: Pubmed

      • Divide and conquer: Evaluation of a redesign of a pediatric teaching service. Pediatr Blood Cancer. 2019 07; 66(7):e27738. View in: Pubmed

      • Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study. J Clin Oncol. 2019 04 01; 37(10):770-779. View in: Pubmed

      • Fluctuations in dietary intake during treatment for childhood leukemia: A report from the DALLT cohort. Clin Nutr. 2019 12; 38(6):2866-2874. View in: Pubmed

      • A single institutional review of pediatric Bacillus spp. bloodstream infections demonstrates increased incidence among children with cancer. Pediatr Blood Cancer. 2019 04; 66(4):e27568. View in: Pubmed

      • Trypsin-encoding PRSS1-PRSS2 variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report. Haematologica. 2019 03; 104(3):556-563. View in: Pubmed

      • PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J Exp Med. 2018 12 03; 215(12):3094-3114. View in: Pubmed

      • Health Status and Health-related Quality of Life Measurement in Pediatric Cancer Clinical Trials: An Examination of the DFCI 00-01 Acute Lymphoblastic Leukemia Protocol. J Pediatr Hematol Oncol. 2018 11; 40(8):580-587. View in: Pubmed

      • Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations. Am J Hematol. 2018 11; 93(11):1358-1367. View in: Pubmed

      • Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. Blood Adv. 2018 06 26; 2(12):1449-1458. View in: Pubmed

      • Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001. Pediatr Blood Cancer. 2018 10; 65(10):e27256. View in: Pubmed

      • Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. J Clin Oncol. 2018 08 01; 36(22):2306-2314. View in: Pubmed

      • Reply to comment on: Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018 08; 65(8):e27082. View in: Pubmed

      • Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018 07; 65(7):e27062. View in: Pubmed

      • Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. Leukemia. 2018 10; 32(10):2126-2137. View in: Pubmed

      • Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. Blood Adv. 2018 03 13; 2(5):529-533. View in: Pubmed

      • Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia. Int J Lab Hematol. 2018 Jun; 40(3):343-351. View in: Pubmed

      • Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018 05; 65(5):e26952. View in: Pubmed

      • Influence of BCL2L11 polymorphism on osteonecrosis during treatment of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2019 02; 19(1):33-41. View in: Pubmed

      • Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):259-264. View in: Pubmed

      • Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol. Leukemia. 2017 12; 31(12):2854. View in: Pubmed

      • An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001. Pediatr Blood Cancer. 2018 03; 65(3). View in: Pubmed

      • TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia. Cancer Discov. 2017 11; 7(11):1336-1353. View in: Pubmed

      • Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. Blood. 2017 10 05; 130(14):1620-1627. View in: Pubmed

      • Phase I Study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. Blood. 2017 Aug 09. View in: Pubmed

      • Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study. Lancet Oncol. 2017 09; 18(9):1238-1248. View in: Pubmed

      • Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients. Oncotarget. 2017 Jul 04; 8(27):43752-43767. View in: Pubmed

      • Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. Cell Stem Cell. 2017 03 02; 20(3):315-328.e7. View in: Pubmed

      • A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2017 Jul; 64(7). View in: Pubmed

      • Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2017 01; 17(1):107. View in: Pubmed

      • Synchronous occurrence of acute lymphoblastic leukemia and wilms tumor in two patients: underlying etiology and combined treatment plan. Pediatr Blood Cancer. 2017 05; 64(5). View in: Pubmed

      • Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2017 Feb 15; 23(4):1012-1024. View in: Pubmed

      • Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia. Support Care Cancer. 2017 02; 25(2):449-457. View in: Pubmed

      • Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances. Curr Hematol Malig Rep. 2016 10; 11(5):385-94. View in: Pubmed

      • How Variable Is Our Delivery of Information? Approaches to Patient Education About Oral Chemotherapy in the Pediatric Oncology Clinic. J Pediatr Health Care. 2017 Jan - Feb; 31(1):e1-e6. View in: Pubmed

      • The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183. View in: Pubmed

      • Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol. 2016 06; 17(6):e231-e239. View in: Pubmed

      • The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586. View in: Pubmed

      • Dietary intake and childhood leukemia: The Diet and Acute Lymphoblastic Leukemia Treatment (DALLT) cohort study. Nutrition. 2016 Oct; 32(10):1103-1109.e1. View in: Pubmed

      • Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016 Mar; 101(3):279-85. View in: Pubmed

      • A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clin Cancer Res. 2016 Aug 15; 22(16):4014-22. View in: Pubmed

      • Impact of Socioeconomic Status on Timing of Relapse and Overall Survival for Children Treated on Dana-Farber Cancer Institute ALL Consortium Protocols (2000-2010). Pediatr Blood Cancer. 2016 Jun; 63(6):1012-8. View in: Pubmed

      • Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. Cancer. 2016 Mar 15; 122(6):946-53. View in: Pubmed

      • Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy. J Clin Oncol. 2016 Mar 20; 34(9):919-26. View in: Pubmed

      • Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015 Dec; 16(16):1677-90. View in: Pubmed

      • Bacillus cereus Cerebral Abscess During Induction Chemotherapy for Childhood Acute Leukemia. J Pediatr Hematol Oncol. 2015 Oct; 37(7):568-9. View in: Pubmed

      • Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia. Pediatr Blood Cancer. 2016 Feb; 63(2):228-33. View in: Pubmed

      • Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol. Leukemia. 2016 05; 30(5):1184-7. View in: Pubmed

      • Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2016 11; 16(6):530-535. View in: Pubmed

      • Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol. 2015 Sep 20; 33(27):2938-48. View in: Pubmed

      • Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):29-41. View in: Pubmed

      • Cytogenetic Variation of B-Lymphoblastic Leukemia With Intrachromosomal Amplification of Chromosome 21 (iAMP21): A Multi-Institutional Series Review. Am J Clin Pathol. 2015 Jul; 144(1):103-12. View in: Pubmed

      • Epigenetic and molecular signatures of cord blood CD34(+) cells treated with histone deacetylase inhibitors. Vox Sang. 2016 Jan; 110(1):79-89. View in: Pubmed

      • Polymorphisms in Genes Related to Oxidative Stress Are Associated With Inferior Cognitive Function After Therapy for Childhood Acute Lymphoblastic Leukemia. J Clin Oncol. 2015 Jul 01; 33(19):2205-11. View in: Pubmed

      • CNS prophylaxis in pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2014 Dec 05; 2014(1):198-201. View in: Pubmed

      • Balancing cure and long-term risks in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2014 Dec 05; 2014(1):190-7. View in: Pubmed

      • Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science. 2014 Dec 12; 346(6215):1373-7. View in: Pubmed

      • Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015 Mar; 29(3):526-34. View in: Pubmed

      • Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014 Sep; 4(9):1074-87. View in: Pubmed

      • Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia. Clin Cancer Res. 2015 Jan 15; 21(2):329-34. View in: Pubmed

      • Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014 Jun; 15(8):1105-16. View in: Pubmed

      • Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet. 2014 Jun; 46(6):618-23. View in: Pubmed

      • Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun. 2014 Mar 24; 5:3469. View in: Pubmed

      • Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia. Leukemia. 2014 Sep; 28(9):1819-27. View in: Pubmed

      • Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial. Pediatr Blood Cancer. 2014 Jul; 61(7):1232-8. View in: Pubmed

      • c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood. 2014 Feb 13; 123(7):1040-50. View in: Pubmed

      • Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014 Jan 02; 123(1):70-7. View in: Pubmed

      • Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model. Leuk Res. 2014 Feb; 38(2):258-62. View in: Pubmed

      • Impact of promoter polymorphisms in key regulators of the intrinsic apoptosis pathway on the outcome of childhood acute lymphoblastic leukemia. Haematologica. 2014 Feb; 99(2):314-21. View in: Pubmed

      • Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia. Clin Cancer Res. 2013 Sep 15; 19(18):5240-9. View in: Pubmed

      • Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer. 2013 Oct 01; 119(19):3555-62. View in: Pubmed

      • Neuropsychological outcomes of a randomized trial of prednisone versus dexamethasone in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute All Consortium Protocol 00-01. Pediatr Blood Cancer. 2013 Nov; 60(11):1785-91. View in: Pubmed

      • Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer. Am J Cancer Res. 2013; 3(3):323-38. View in: Pubmed

      • Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. J Clin Oncol. 2013 Jul 01; 31(19):2469-76. View in: Pubmed

      • Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013 Mar 20; 31(9):1202-10. View in: Pubmed

      • Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes. Pediatrics. 2012 Dec; 130(6):1003-11. View in: Pubmed

      • Hematopoietic stem cell transplantation in unique pediatric populations: adolescents, infants, and children with down syndrome. Biol Blood Marrow Transplant. 2013 Jan; 19(1 Suppl):S52-7. View in: Pubmed

      • The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7-9, 2011. Pediatr Blood Cancer. 2013 Feb; 60(2):344-8. View in: Pubmed

      • Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood. 2012 Sep 06; 120(10):2076-86. View in: Pubmed

      • Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Nov; 59(5):925-7. View in: Pubmed

      • Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med. 2012 Apr 12; 366(15):1371-81. View in: Pubmed

      • Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia. Leukemia. 2012 Aug; 26(8):1881-3. View in: Pubmed

      • Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012 Apr 01; 30(10):1042-9. View in: Pubmed

      • Health-related quality of life among children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Oct; 59(4):717-24. View in: Pubmed

      • Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011 Nov 25; 334(6059):1129-33. View in: Pubmed

      • ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. Blood. 2011 Nov 24; 118(22):5883-90. View in: Pubmed

      • Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011 Dec 01; 118(23):6043-9. View in: Pubmed

      • The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. Blood. 2011 Oct 13; 118(15):4169-73. View in: Pubmed

      • Childhood T-all: it's time to move on. Blood. 2011 Jul 28; 118(4):828-9. View in: Pubmed

      • Neuropsychological outcomes of standard risk and high risk patients treated for acute lymphoblastic leukemia on Dana-Farber ALL consortium protocol 95-01 at 5 years post-diagnosis. Pediatr Blood Cancer. 2012 May; 58(5):758-65. View in: Pubmed

      • Impact of HFE mutations on cardiac status in survivors of childhood high-risk ALL: Dana-Farber Cancer Institute Childhood ALL 05-159. J Clin Oncol. 2011 May 20; 29(15_suppl):9508. View in: Pubmed

      • L-asparaginase (L-ASP)-related toxicities with Erwinia L-ASP in a large compassionate-use protocol. J Clin Oncol. 2011 May 20; 29(15_suppl):9534. View in: Pubmed

      • Changes in cardiovascular signaling proteins during doxorubicin treatment in children with high-risk ALL. J Clin Oncol. 2011 May 20; 29(15_suppl):9551. View in: Pubmed

      • Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. Pediatr Blood Cancer. 2011 Sep; 57(3):492-8. View in: Pubmed

      • The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer. 2011 Jun; 47(9):1373-9. View in: Pubmed

      • Therapeutic modalities for patients with lower-risk myelodysplastic syndromes: current options and future directions. Curr Hematol Malig Rep. 2011 Mar; 6(1):5-12. View in: Pubmed

      • The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011 Feb; 152(4):452-9. View in: Pubmed

      • Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol. 2010 Nov 01; 28(31):4755-61. View in: Pubmed

      • Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010 Oct; 11(10):950-61. View in: Pubmed

      • L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011 Jan 15; 117(2):238-49. View in: Pubmed

      • Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukaemia. Br J Haematol. 2010 Nov; 151(3):288-91. View in: Pubmed

      • Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):3816-23. View in: Pubmed

      • Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference. Pediatr Blood Cancer. 2010 Jul 01; 54(7):872-8. View in: Pubmed

      • Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood. 2010 Oct 14; 116(15):2644-50. View in: Pubmed

      • Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010 Feb; 54(2):199-205. View in: Pubmed

      • Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood. 2010 Apr 08; 115(14):2845-51. View in: Pubmed

      • Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010 Feb 01; 28(4):562-9. View in: Pubmed

      • Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia. 2010 Feb; 24(2):320-34. View in: Pubmed

      • Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010 Feb 18; 115(7):1351-3. View in: Pubmed

      • Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents. Leuk Res. 2009 Dec; 33 Suppl 2:S18-21. View in: Pubmed

      • DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia. Clin Cancer Res. 2009 Nov 15; 15(22):6931-8. View in: Pubmed

      • Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors. Am J Hematol. 2009 Oct; 84(10):688-9. View in: Pubmed

      • Treating childhood leukemia without cranial irradiation. N Engl J Med. 2009 Sep 24; 361(13):1310; author reply 1311-2. View in: Pubmed

      • A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia. 2009 Dec; 23(12):2259-64. View in: Pubmed

      • Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. Blood. 2009 Oct 29; 114(18):3764-8. View in: Pubmed

      • Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2009 Aug; 53(2):162-7. View in: Pubmed

      • Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. 2009 Sep 24; 114(13):2764-73. View in: Pubmed

      • Gender differences in long-term dexrazoxane cardioprotection in doxorubicin-treated children with acute lymphoblastic leukemia. J Clin Oncol. 2009 May 20; 27(15_suppl):10005. View in: Pubmed

      • High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009 Jul 16; 114(3):647-50. View in: Pubmed

      • Childhood acute lymphoblastic leukemia: update on prognostic factors. Curr Opin Pediatr. 2009 Feb; 21(1):1-8. View in: Pubmed

      • The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant. 2009 Feb; 15(2):137-72. View in: Pubmed

      • Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). Cancer. 2009 Jan 01; 115(1):84-93. View in: Pubmed

      • Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update. Ecancermedicalscience. 2008; 2:121. View in: Pubmed

      • H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008 Nov 04; 14(5):355-68. View in: Pubmed

      • Acute lymphoblastic leukemia in adolescents and young adults. Curr Hematol Malig Rep. 2008 Jul; 3(3):161-6. View in: Pubmed

      • Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol. 2008 Mar 01; 26(7):1106-11. View in: Pubmed

      • Aggressive Langerhans cell histiocytosis following T-ALL: clonally related neoplasms with persistent expression of constitutively active NOTCH1. Am J Hematol. 2008 Feb; 83(2):116-21. View in: Pubmed

      • Alu elements mediate MYB gene tandem duplication in human T-ALL. J Exp Med. 2007 Dec 24; 204(13):3059-66. View in: Pubmed

      • Acute lymphoblastic leukemia in infancy. Pediatr Blood Cancer. 2007 Dec; 49(7 Suppl):1070-3. View in: Pubmed

      • Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. J Clin Oncol. 2007 Nov 01; 25(31):4914-21. View in: Pubmed

      • A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007 Jul 21; 370(9583):240-250. View in: Pubmed

      • Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood. 2007 Sep 01; 110(5):1607-11. View in: Pubmed

      • Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood. 2007 Aug 15; 110(4):1112-5. View in: Pubmed

      • Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol. 2007 Mar 01; 25(7):813-9. View in: Pubmed

      • Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007 Feb 01; 109(3):896-904. View in: Pubmed

      • Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006 Aug 20; 24(24):3895-903. View in: Pubmed

      • A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol. 2006 Jun 20; 24(18_suppl):6585. View in: Pubmed

      • Phase I study of ON 01910.Na by 3-day continuous infusion (CI) in patients (pts) with advanced cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):13137. View in: Pubmed

      • Outcome of adolescents with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols, 1991-2000. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9023. View in: Pubmed

      • Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood. 2006 Jun 01; 107(11):4508-13. View in: Pubmed

      • Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias. Br J Haematol. 2005 Oct; 131(2):185-92. View in: Pubmed

      • Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia. Blood. 2005 Sep 01; 106(5):1749-54. View in: Pubmed

      • Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol. 2005 May; 45(5):597-602. View in: Pubmed

      • No prognostic effect of additional chromosomal abnormalities in children with acute lymphoblastic leukemia and 11q23 abnormalities. Leukemia. 2005 Apr; 19(4):557-63. View in: Pubmed

      • Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol. 2005 Mar; 33(3):286-94. View in: Pubmed

      • Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood. 2005 Feb 01; 105(3):994-6. View in: Pubmed

      • Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004 Oct 08; 306(5694):269-71. View in: Pubmed

      • Diffusion systems for evaluation of biomineralization. Calcif Tissue Int. 2004 Dec; 75(6):494-501. View in: Pubmed

      • Echocardiographic (Echo) monitoring of myocardial injury during doxorubicin (DOX) therapy for childhood acute lymphoblastic leukemia (ALL). J Clin Oncol. 2004 Jul 15; 22(14_suppl):8505. View in: Pubmed

      • The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004 Jul 08; 351(2):145-53. View in: Pubmed

      • Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk Res. 2004 Jul; 28(7):679-89. View in: Pubmed

      • Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neurotoxicity. J Clin Oncol. 2004 Jul 01; 22(13):2701-7. View in: Pubmed

      • Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia. 2004 Apr; 18(4):693-702. View in: Pubmed

      • Utilization of Ig heavy chain variable, diversity, and joining gene segments in children with B-lineage acute lymphoblastic leukemia: implications for the mechanisms of VDJ recombination and for pathogenesis. Blood. 2004 Jun 15; 103(12):4602-9. View in: Pubmed

      • FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 2004 May 01; 103(9):3544-6. View in: Pubmed

      • Management of an anaphylactoid reaction to methotrexate with a stepwise graded challenge. Pediatr Allergy Immunol. 2003 Oct; 14(5):409-11. View in: Pubmed

      • Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003 Oct 01; 21(19):3616-22. View in: Pubmed

      • Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection. Blood. 2003 Dec 15; 102(13):4520-6. View in: Pubmed

      • Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment. J Clin Oncol. 2003 Aug 01; 21(15):2953-60. View in: Pubmed

      • Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment. Curr Opin Hematol. 2003 Jul; 10(4):290-6. View in: Pubmed

      • Childhood leukemia: electric and magnetic fields as possible risk factors. Environ Health Perspect. 2003 Jun; 111(7):962-70. View in: Pubmed

      • Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. Cancer. 2003 Apr 15; 97(8):1920-8. View in: Pubmed

      • Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia. 2003 Apr; 17(4):700-6. View in: Pubmed

      • SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003 Aug 01; 102(3):795-801. View in: Pubmed

      • Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood. 2003 Jul 01; 102(1):262-8. View in: Pubmed

      • Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003 Feb; 3(2):173-83. View in: Pubmed

      • Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clin Cancer Res. 2002 Sep; 8(9):2812-9. View in: Pubmed

      • Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002 Jun 01; 359(9321):1909-15. View in: Pubmed

      • Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002 May 15; 20(10):2429-40. View in: Pubmed

      • Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002 May 15; 20(10):2441-52. View in: Pubmed

      • Accelerated superfractionated radiotherapy with concomitant boost for locally advanced head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2002 Mar 15; 52(4):918-28. View in: Pubmed

      • Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. J Clin Oncol. 2002 Jan 01; 20(1):237-46. View in: Pubmed

      • Breast cancer in HIV-positive women: a report of four cases and review of the literature. Cancer Invest. 2002; 20(4):452-7. View in: Pubmed

      • Pediatric Cancer CareLink--supporting home management of childhood leukemia. Proc AMIA Symp. 2002; 290-4. View in: Pubmed

      • MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002 Jan; 30(1):41-7. View in: Pubmed

      • Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01. Cancer. 2001 Jul 01; 92(1):15-22. View in: Pubmed

      • Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol. 2001 Jun 15; 19(12):3066-72. View in: Pubmed

      • Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001 Mar 01; 97(5):1211-8. View in: Pubmed

      • Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia. 2000 Dec; 14(12):2247-56. View in: Pubmed

      • Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. J Pediatr Hematol Oncol. 2000 May-Jun; 22(3):206-13. View in: Pubmed

      • Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer. 2000 Apr 15; 88(8):1964-9. View in: Pubmed

      • Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000 Apr 06; 342(14):998-1006. View in: Pubmed

      • Induction failure in acute lymphoblastic leukemia of childhood. Cancer. 1999 Mar 15; 85(6):1395-404. View in: Pubmed

      • Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood. 1998 Dec 15; 92(12):4792-7. View in: Pubmed

      • Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer. 1997 Dec 15; 80(12):2285-95. View in: Pubmed

      • Treatment of childhood leukemia. Curr Opin Oncol. 1997 Jan; 9(1):26-33. View in: Pubmed

      • Cisplatin-based chemotherapy in renal transplant recipients. A case report and a review of the literature. Cancer. 1996 Jan 01; 77(1):160-3. View in: Pubmed

      • Jumping translocations in leukemia. Leukemia. 1995 Apr; 9(4):634-9. View in: Pubmed

      • Members of the src family of nonreceptor tyrosine kinases share a common mechanism for membrane binding. Cell Growth Differ. 1993 Jun; 4(6):475-82. View in: Pubmed

      • Chromosome 21 rearrangement in acute biphenotypic leukemia. Cancer Genet Cytogenet. 1992 Nov; 64(1):56-9. View in: Pubmed

      • del(5q) in acute lymphoblastic leukemia with biphenotypic and early progenitor phenotype. Cancer Genet Cytogenet. 1992 Oct 15; 63(2):89-94. View in: Pubmed

      • Binding of pp60v-src to membranes: evidence for multiple membrane interactions. Biochem Cell Biol. 1992 Oct-Nov; 70(10-11):1187-92. View in: Pubmed

      • Lysine residues form an integral component of a novel NH2-terminal membrane targeting motif for myristylated pp60v-src. J Cell Biol. 1992 Oct; 119(2):415-25. View in: Pubmed

      • Developmental regulation of transmembrane signaling via the T cell antigen receptor/CD3 complex in human T lymphocytes. J Immunol. 1992 Mar 01; 148(5):1315-21. View in: Pubmed

      • Chemotherapy of metastatic Merkel cell cancer. Cancer Invest. 1991; 9(2):129-32. View in: Pubmed

      • Increased permissivity of monkey cells to human adenovirus multiplication is affected by culturing conditions and correlates with both synthesis of virion fiber protein and altered splicing of its mRNA. Virology. 1989 Nov; 173(1):109-19. View in: Pubmed

      • Characterization of the translational defect to fiber synthesis in monkey cells abortively infected with human adenovirus: role of ancillary leaders. J Virol. 1989 Oct; 63(10):4376-85. View in: Pubmed

      • Mechanisms of T cell activation by the calcium ionophore ionomycin. J Immunol. 1989 Aug 15; 143(4):1283-9. View in: Pubmed

      • Mechanism of mononuclear cell activation by an anti-CD43 (sialophorin) agonistic antibody. J Immunol. 1989 Jun 15; 142(12):4194-200. View in: Pubmed

      • GANGLIONEUROBLASTOMA. STUDIES OF PATHOLOGIC CHANGES AND CONTENT OF CATECHOLAMINE. Am J Clin Pathol. 1964 Aug; 42:144-51. View in: Pubmed

      • Large adenomatous polyp of Brunner's glands. Am J Clin Pathol. 1961 Nov; 36:438-43. View in: Pubmed

      • A Low-resistance Valve and Indicating Flowmeter for Respiratory Measurements. Science. 1946 Apr 26; 103(2678):537-9. View in: Pubmed

      • A low-resistance valve and indicating flowmeter for respiratory measurements. Science. 1946 Apr 26; 103(2678):537-9. View in: Pubmed

      • A NEW METHOD FOR STUDYING BREATHING, WITH OBSERVATIONS UPON NORMAL AND ABNORMAL SUBJECTS. J Clin Invest. 1944 Nov; 23(6):907-13. View in: Pubmed

      Locations

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Shields Warren 320 Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Shields Warren 320 Boston, MA 02215
      Get Direction
      42.3374, -71.1082

      Ratings and Comments

      Lewis B. Silverman, MD

      About Our Ratings

      Physician Star Rating Comment Block